Fulminant lymphocytic myocarditis: Prediction of successful weaning from Impella support for cardiogenic shock

Published:September 15, 2021DOI:https://doi.org/10.1016/j.jccase.2021.08.005

      Abstract

      We present a series of four patients with biopsy-proven fulminant lymphocytic myocarditis with cardiogenic shock and discuss whether it is possible to predict recovery of left ventricular function and successful weaning at the time of initial placement of mechanical circulatory support. Impella CP (Abiomed, Danvers, MA, USA) was placed in these patients on admission. Patients 1 and 2 made complete recovery. Patient 3 proceeded to bi-ventricular assist device and is currently waiting for transplantation. Patient 4 proceeded to Impella 5 but died from multiple organ failure. Although the Impella provides excellent hemodynamic support, outcomes of the patients with fulminant myocarditis with Impella support may depend upon the severity of myocarditis and myocardial failure. In addition to the previously reported predictors such as the level of elevated biomarkers, the severity of ventricular wall edema, and the development of rhythm disturbances, the absence of right ventricular dysfunction seems important to predict successful weaning from Impella support.

      Keywords

      To read this article in full you will need to make a payment

      References

        • Kociol RD
        • Cooper LT
        • Fang JC
        • Moslehi JJ
        • Pang PS
        • Sabe MA
        • Shah RV
        • Sims DB
        • Thiene G
        For the American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology. Recognition and initial management of fulminant myocarditis: a scientific statement from the American Heart Association.
        Circulation. 2020; 141: e69-e92
        • Kindermann I
        • Barth C
        • Mahfound F
        • Ukena C
        • Lenski M
        • Yilmaz A
        • Klingel K
        • Kandolf R
        • Sechtem U
        • Cooper LT
        • Böhm M.
        Update on myocarditis.
        J Am Coll Cardiol. 2012; 59: 779-792
        • Caforio ALP
        • Pankuweit S
        • Arbustini E
        • Basso C
        • Gimeno-Blanes J
        • Felix SB
        • Fu M
        • Heliö T
        • Heymans S
        • Jahns R
        • Klingel K
        • Linhart A
        • Maisch B
        • McKenna W
        • Mogensen J
        • et al.
        Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.
        Eur Heart J. 2013; 34: 2636-2648
        • Sjauw KD
        • Konorza T
        • Erbel R
        • Danna PL
        • Viecca M
        • Minden H-H
        • Butter C
        • Engstrom T
        • Hassager C
        • Machado FP
        • Pedrazzini G
        • Wanger DR
        • Schamberger R
        • Kerber S
        • Mathey DG
        • et al.
        Supported high-risk percutaneous coronary intervention with the Impella 2.5 device: the Europella registry.
        J Am Coll Cardiol. 2009; 54: 2430-2434
        • McCarthy RE
        • Boehmer JP
        • Hruban RH
        • Hutchins GM
        • Kasper EK
        • Hare JM
        • Banghman KL.
        Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis.
        N Engl J Med. 2000; 342: 690-695
        • Ammirati E
        • Veronese G
        • Branbatti M
        • Merlo M
        • Cipriani M
        • Potena L
        • Sormani P
        • Aoki T
        • Sugimura K
        • Sawamura A
        • Okumura T
        • Pinney S
        • Horg K
        • Shah P
        • Braun Ӧ
        • et al.
        Fulminant versus acute nonfulminant myocarditis in patients with left ventricular dysfunction.
        J Am Coll Cardiol. 2019; 74: 299-311
        • Prondzinsky R
        • Unverzagt S
        • Russ M
        • Lemm H
        • Swyter M
        • Wegener N
        • Buerke U
        • Raaz U
        • Ebelt H
        • Schmitt A
        • Heinroth K
        • Haerting J
        • Werdan K
        • Buerke M.
        Hemodynamic effects of intra-aortic balloon counter pulsation in patients with acute myocardial infarction complicated by cardiogenic shock: the prospective, randomized intra-aortic balloon pump shock trial.
        Shock. 2012; 37: 378-384
        • Russo JJ
        • Aleksova N
        • Pitcher I
        • Couture E
        • Parlow S
        • Faraz M
        • Visintni S
        • Simard T
        • Di Santo P
        • Mathew R
        • So DY
        • Takeda K
        • Garan AR
        • Karmpaliotis D
        • Takayama H
        • et al.
        Left ventricular unloading during extracorporeal membrane oxygenation in patients with cardiogenic shock.
        J Am Coll Cardiol. 2019; 73: 654-662
        • O'Neill WW
        • Kleiman NS
        • Moses J
        • Henriques JPS
        • Dixon S
        • Massaro J
        • Palacios I
        • Maini B
        • Mulukutla S
        • Dzavik V
        • Pompa J
        • Douglas P
        • Ohman M.
        A prospective randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention: the PROTECT II study.
        Circulation. 2012; 126: 1717-1727
        • Matsumoto M
        • Asaumi Y
        • Nakamura Y
        • Nakatani T
        • Nagai T
        • Kanaya T
        • Kawakami S
        • Honda S
        • Kataoka Y
        • Nakajima S
        • Seguchi O
        • Yanase M
        • Nishimura K
        • Miyamoto Y
        • Kusano K
        • et al.
        Clinical determinants of successful weaning from extracorporeal membrane oxygenation in patients with fulminant myocarditis.
        ESC Heart Failure. 2018; 5: 675-684